## **1** Integrated methylome and phenome study of the circulating proteome

# 2 reveals markers pertinent to brain health

- Danni A Gadd<sup>1</sup>, Robert F Hillarv<sup>1</sup>, Daniel L McCartnev<sup>1</sup>, Liu Shi<sup>2</sup>, Aleks Stolicvn<sup>3</sup>, Neil Robertson<sup>4</sup>, 3 Rosie M Walker<sup>5</sup>, Robert I McGeachan<sup>6</sup>, Archie Campbell<sup>1</sup>, Shen Xueyi<sup>3</sup>, Miruna C Barbu<sup>3</sup>, Claire 4 Green<sup>3</sup>, Stewart W Morris<sup>1</sup>, Mathew A Harris<sup>3</sup>, Ellen V Backhouse<sup>5</sup>, Joanna M Wardlaw<sup>5,7,8,9</sup>, J 5 Douglas Steele<sup>10</sup>, Diego A Oyarzún<sup>11,12,13</sup>, Graciela Muniz-Terrera<sup>14</sup>, Craig Ritchie<sup>14</sup>, Alejo Nevado-6 Holgado<sup>2</sup>, Tamir Chandra<sup>4</sup>, Caroline Hayward<sup>1,15</sup>, Kathryn L Evans<sup>1</sup>, David J Porteous<sup>1</sup>, Simon R 7 Cox<sup>16,17</sup>, Heather C Whalley<sup>3</sup>, Andrew M McIntosh<sup>3</sup>, Riccardo E Marioni<sup>1,†</sup> 8 9 <sup>1</sup> Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, EH4 2XU 10 <sup>2</sup> Department of Psychiatry, University of Oxford, UK, OX3 7JX 11 <sup>3</sup> Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, EH10 5HF, UK 12 <sup>4</sup> MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, EH4 2XU <sup>5</sup> Centre for Clinical Brain Sciences, Chancellor's Building, 49 Little France Crescent, Edinburgh BioQuarter, Edinburgh, EH16 4SB 13 14 <sup>6</sup> Centre for Discovery Brain Sciences, University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, UK 15 <sup>7</sup> Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK 16 <sup>8</sup> Edinburgh Imaging, University of Edinburgh, Edinburgh, UK 17 <sup>9</sup> UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK, EH8 9JZ 18 <sup>10</sup> Division of Imaging Science and Technology, Medical School, University of Dundee, Dundee, UK, DD1 9SY 19 <sup>11</sup> School of Informatics, University of Edinburgh, Edinburgh, EH8 9AB 20 <sup>12</sup> School of Biological Sciences, University of Edinburgh, Edinburgh, EH3 3JF 21 <sup>13</sup> The Alan Turing Institute, 96 Euston Road, London, NW1 2DB 22 <sup>14</sup> Centre for Clinical Brain Sciences, Edinburgh Dementia Prevention, University of Edinburgh, Edinburgh, UK, EH4 2XU 23 <sup>15</sup> Medical Research Council Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, EH4 2XU 24 <sup>16</sup> Lothian Birth Cohorts, University of Edinburgh, Edinburgh, EH8 9JZ 25 <sup>17</sup> Department of Psychology, University of Edinburgh, Edinburgh, EH8 9JZ
- 26 <sup>†</sup> Corresponding author: Riccardo Marioni, riccardo.marioni@ed.ac.uk

### 27 Abstract

28

29 Characterising associations between the methylome, proteome and phenome may provide insight 30 into biological pathways governing brain health. Here, we report an integrated DNA methylation and 31 phenotypic study of the circulating proteome in relation to brain health. Methylome-wide association 32 studies of 4,058 plasma proteins are performed (N=774), identifying 2,928 CpG-protein associations 33 after adjustment for multiple testing. These were independent of known genetic protein quantitative 34 trait loci (pQTLs) and common lifestyle effects. Phenome-wide association studies of each protein 35 are then performed in relation to 15 neurological traits (N=1,065), identifying 405 associations 36 between the levels of 191 proteins and cognitive scores, brain imaging measures or APOE e4 status. 37 We uncover 35 previously unreported DNA methylation signatures for 17 protein markers of brain 38 health. The epigenetic and proteomic markers we identify are pertinent to understanding and 39 stratifying brain health.

## 40 Introduction

The health of the ageing brain is associated with risk of neurodegenerative disease <sup>1,2</sup>. Relative brain
age – a measure of brain health calculated using multiple volumetric brain imaging measures – has
recently been shown to predict the development of dementia <sup>3</sup>. Structural brain imaging and
performance in cognitive tests are well-characterised markers of brain health <sup>4</sup>, which clearly
associate with potentially modifiable traits such as body mass index (BMI), smoking and diabetes <sup>5-7</sup>.
Understanding the interplay between environment, biology and brain health may therefore inform
preventative strategies.

Multiple layers of omics data indicate the biological pathways that underlie phenotypes. Proteomic
blood sampling can track peripheral pathways that may impact brain health, or record proteins
secreted from the brain into the circulatory system. Although proteome-wide characterisation of
cognitive decline and dementia risk <sup>8-10</sup> have been facilitated at large-scale by SOMAscan<sup>®</sup> protein

52	measurements, there is a need to further integrate omics to characterise brain health phenotypes.
53	Epigenetic modifications to the genome record an individual's response to environmental exposures,
54	stochastic biological effects, and genetic influences. Epigenetic changes include histone
55	modifications, non-coding RNA, chromatin remodelling, and DNA methylation (DNAm) at cytosine
56	bases, such as 5-hydroxymethylcytosine. These are implicated in changes to chromatin structure and
57	the regulation of pathways associated with neurological diseases <sup>11,12</sup> . However, DNAm at cytosine-
58	guanine (CpG) dinucleotides is the most widely profiled blood-based epigenetic modification at large
59	scale.

60 Modifications to DNAm at CpG sites play differential roles in influencing gene expression at the 61 transcriptional level <sup>13</sup>. Additionally, DNAm accounts for inter-individual variability in circulating protein levels <sup>14–16</sup>. Recently, through integration of DNAm and protein data, we have shown that 62 63 epigenetic scores for plasma protein levels – known as 'EpiScores' – associate with brain morphology and cognitive ageing markers <sup>17</sup> and predict the onset of neurological diseases <sup>18</sup>. These 64 65 studies highlight that while datasets that allow for integration of proteomic, epigenetic and 66 phenotypic information are rarely-available, they hold potential to advance risk stratification. 67 Integration may also uncover candidate biological pathways that may underlie brain health.

68 Associations between protein levels and DNAm at CpGs are known as protein quantitative trait 69 methylation loci (pQTMs) and can be quantified by methylome-wide association studies (MWAS) of protein levels. The largest MWAS of protein levels to date assessed 1,123 SOMAmer protein 70 measurements in the German KORA cohort  $(n=944)^{14}$ . In that study, Zaghlool *et al* reported 98 71 72 pQTMs that replicated in the QMDiab cohort (n=344), with significant associations between DNAm at the immune-associated locus NLRC5 and seven immune-related proteins ( $P \square < \square 2.5 \square × \square 10^{-7}$ ). 73 74 This suggested that DNAm not only reflects variability in the proteome but is closely related to 75 chronic systemic inflammation. Hillary *et al* have also assessed epigenetic signatures for 281

SOMAmer protein measurements that were previously associated with Alzheimer's disease, in the
 Generation Scotland cohort that we utilised in this study <sup>19</sup>. However, proteome-wide assessment of
 pQTMs has not been tested against a comprehensive spectrum of brain health traits.

79 Here, we conduct an integrated methylome- and phenome-wide assessment of the circulating 80 proteome in relation to brain health (Fig. 1), using 4,058 protein level measurements (Supplementary 81 Table 1). We characterise CpG-protein associations (pOTMs) for these proteins in 774 individuals 82 from the Generation Scotland cohort using EPIC array DNAm at 772,619 CpG sites. We then 83 identify which of the 4,058 protein levels associate with one or more of 15 neurological traits (seven 84 structural brain imaging measures, seven cognitive scores and APOE e4 status) in 1,065 individuals 85 from the same cohort where the pQTM data are a nested subset. By integrating these datasets, we 86 probe the epigenetic signatures of proteins that are related to brain health. For these signatures, we 87 map potential underlying genetic components and chromatin interactions that may play a role in 88 protein level regulation. A YouTube video summarising the study and detailing access to the datasets 89 can be viewed at https://www.youtube.com/channel/UCxQrFFTIItF25YKfJTXuumQ.

## 90 **Results**

### 91 Methylome-wide studies of 4,058 plasma proteins

92 We conducted MWAS to test for pQTM associations between 772,619 CpG sites and 4,058

93 circulating protein levels (corresponding to 4,235 SOMAmer measurements; Supplementary Table

1). The MWAS population included 774 individuals from Generation Scotland (mean age 60 years

- 95 [SD 8.8], 56% Female; Supplementary Table 2). 143 principal components explained 80% of the
- 96 cumulative variance in the 4,235 measurements (Supplementary Fig. 1 and Supplementary Table 3).
- 97 A threshold for multiple testing based on these components was applied across all MWAS (P <

98  $0.05/(143x772,619) = 4.5x10^{-10}$ ).

99	In our basic model adjusting for age, sex and available genetic pQTL effects from Sun <i>et al</i> <sup>20</sup>
100	238,245 pQTMs (2,107 <i>cis</i> and 236,138 <i>trans</i> , representing 0.005% of tested associations) had P <
101	$4.5 \times 10^{-10}$ (Supplementary Table 4). In our second model that further adjusted for Houseman-
102	estimated white blood cell proportions <sup>21</sup> , there were 3,213 associations (453 <i>cis</i> and 2,760 <i>trans</i> ) that
103	had $P < 4.5 \times 10^{-10}$ (Supplementary Table 5). Smoking status and BMI are known to have well-
104	characterised DNAm signatures <sup>22,23</sup> ; fully-adjusted models were therefore further adjusted for these
105	factors. There were 2,928 associations (451 cis and 2,477 trans) in the fully-adjusted models
106	(Supplementary Table 6). 2,847 pQTM associations were significant in all models. Figure 2
107	summarises these findings.
108	There were 191 unique proteins with associations in the fully-adjusted models, corresponding to 195
109	SOMAmer measurements (two SOMAmers were present for CLEC11A, GOLM1, ICAM5 and
110	LRP11). Genomic inflation statistics for these 195 SOMAmer measurements (fully-adjusted
111	MWAS) are presented in Supplementary Table 7. In a sensitivity analysis, restriction of the threshold
112	for cis pQTMs from 10Mb to 1Mb from the transcription start site of the gene encoding the protein
113	yielded 409 cis pQTMs (a drop of 42 pQTMs) in the fully-adjusted MWAS. A summary of known
114	pQTLs <sup>24</sup> and a record of whether these were available for adjustment is provided in Supplementary
115	Table 8. Characterising the genomic location of the findings, 46% of cis and 29% of trans pQTMs in
116	the fully-adjusted MWAS involved CpGs positioned in either a CpG Island, Shore or Shelf
117	(Supplementary Table 6).

### 118 Pleiotropic pQTM associations in the fully-adjusted MWAS

119 Pleiotropy was observed for both CpG sites and protein levels (Fig. 3). Nineteen proteins had 10 or

more pQTMs in the fully-adjusted MWAS (Supplementary Table 9). Of the 2,928 pQTMs in the

- 121 fully-adjusted MWAS, 987 involved Pappalysin-1 (PAPPA) and there were a further 1,116 pQTMs
- that involved the Proteoglycan 3 Precursor (PGR3) protein. The remaining 825 pQTMs involved 189

123	unique protein levels, with 434 <i>cis</i> and 391 <i>trans</i> associations (Fig. 2). Principal components
124	analyses indicated high correlations between CpGs associated with the pleiotropic proteins PAPPA
125	and PRG3, whereas the CpGs involved in the remaining 825 pQTMs were largely uncorrelated
126	(Supplementary Fig. 2). pQTM frequencies for the 1,837 unique CpGs selected in the fully-adjusted
127	models, with their respective genes and EWAS catalogue <sup>25</sup> lookup of epigenome-wide significant (P
128	$< 3.6 \times 10^{-8}$ ) phenotypic associations is presented in Supplementary Table 10. Of these CpGs, sites
129	within the NLRC5, SLC7A11 and PARP9 gene regions exhibited the highest levels of pleiotropy (Fig.
130	3).

131 The pleiotropic findings for PAPPA and cg07839457 (NLRC5 gene) replicated previous MWAS results from Zaghlool *et al*<sup>14</sup> (944 individuals, with 1,123 protein SOMAmers). Of the 98 pQTMs 132 133 identified by Zaghlool et al, 81 were comparable (both the protein and CpG sites from the 98 pQTMs 134 were available across both MWAS). Of these 81 pQTMs, 26 replicated at our significance threshold  $(P < 4.5 \times 10^{-10})$  with the same direction of effect, a further 16 replicated at the epigenome-wide 135 significance threshold ( $P < 3.6 \times 10^{-8}$ )<sup>26</sup> and a further 39 replicated at nominal P < 0.05136 137 (Supplementary Table 11 and Supplementary Fig. 3). When accounting for 26 pQTMs that were previously reported by Zaghlool et al and 10 pQTMs that were previously reported by Hillary et al 138 <sup>14,19</sup>, 2,892 of the 2,928 fully-adjusted pQTMs were novel. Of these 2,892 novel pQTMs, 1,109 139 140 involved the levels of 41 proteins that were measured by Zaghlool et al (973 pQTMs for PAPPA and 136 additional pQTMs for the levels of 40 proteins), whereas 1,783 pQTMs involved the levels of 141 142 proteins that were previously unmeasured (1,116 pQTMs for PRG3 and 667 further pQTMs for 148 143 proteins).

#### 144 **Proteome associations with brain health phenotypes**

We next conducted a proteome-wide association study of brain health characteristics (protein
PheWAS of brain imaging, cognitive scoring and *APOE* e4 status, alongside age and sex; Fig. 4).

147	Distribution plots for the seven cognitive scores and seven brain imaging phenotypes are presented in
148	Supplementary Figs. 4-5. A maximum sample of 1,065 individuals was available (mean age 59.9
149	years [SD 9.6], 59% Female; Supplementary Table 2); all 774 individuals from the pQTM study
150	were included in these analyses. A threshold for multiple testing adjustment was calculated based on
151	143 independent components that explained >80% of the 4,235 SOMAmer levels (Supplementary
152	Table 3 and Supplementary Fig. 1). This equated to $P < 0.05/(143) = 3.5 \times 10^{-4}$ . The levels of 587
153	plasma proteins were associated with age and 545 were associated with sex, with 222 proteins
154	common to both phenotypes (Supplementary Table 12). When comparable associations from three
155	studies (with N>1000) were tested <sup>20,27,28</sup> , 97% of age and 98% of sex associations replicated in one
156	or more of studies (Supplementary Table 12).
157	There were 191 unique protein markers that had a total of 405 associations with brain health
158	characteristics (Supplementary Fig. 6 and Fig. 4a). These consisted of 95 brain imaging
159	(Supplementary Table 13), 296 cognitive test score (Supplementary Table 14) and 14 APOE e4
160	status (Supplementary Table 15) associations. Supplementary Table 16 stratifies these associations
161	by direction of effect and Supplementary Table 17 provides full summary statistics for all 405
162	associations. Of the seven brain morphology traits, Relative Brain Age and General Fractional
163	Anisotropy (gFA) had the largest number of associations, with 24 and 22 protein markers identified,
164	respectively. Of the cognitive score traits, Processing Speed and General Cognitive Ability scores
165	were associated with the highest number of protein markers (102 and 73, respectively). The 14
166	APOE e4 status associations are plotted in Supplementary Fig. 7.
167	Stratifying the 405 associations by direction of effect revealed that the majority (89%) of
168	associations indicated that higher levels of the proteins were associated with less favourable brain
169	health (Supplementary Table 16). Eighty-seven of the 405 associations involved protein leves that

were associated with more favourable brain health; this signature included the levels of SLITRK1,

171 NCAN and COL11A2. Higher levels of ASB9, RBL2, HEXB and SMPD1 associated with poorer 172 brain health. Protein interaction network analyses for the genes corresponding to the 191 protein 173 markers (Supplementary Fig. 8) indicated that many of the proteins in these signatures clustered 174 together, implying shared underlying functions. An inflammatory cluster including CRP, ITIH4, C3, 175 C5, COL11A2 and SIGLEC2 was present and higher levels of these markers were associated with 176 poorer brain health outcomes. Gene set enrichment analyses on the 191 genes corresponding to the 177 protein markers (Supplementary Fig. 9) supported the link between many of the proteins associated 178 with poorer brain health and the innate immune system, while also implicating extracellular matrix, 179 lysosomal, metabolic and additional inflammatory pathways. Tissue expression profiles of the 191 180 genes (Supplementary Fig. 10) indicated that many of the markers were expressed non-neurological 181 tissues; however, some proteins were expressed in nervous tissues. Markers such as ASB9 and 182 NCAN were found to be consistently identified across multiple brain imaging traits as markers of 183 poorer and better brain health, respectively (Supplementary Table 16). While many of the 184 associations for brain imaging measures identified proteins that were distinct from those found for 185 cognitive scores and APOE e4 status, 22 protein markers were associated with both a cognitive score 186 and a brain imaging trait (Fig. 4b and Supplementary Table 18). Of these 22 proteins, there were 10 187 principal components that had a cumulative variance of >80% and five components had eigenvalues 188 > 1 (Supplementary Fig. 11). Three APOE e4 status markers (ING4, APOB and CRP) were also 189 associated with cognitive scores (Fig. 4b).

## 190 Replication of protein PheWAS associations

191 Six of the 14 APOE e4 status associations replicated previous SOMAmer protein findings (N

192 SOMAmers= 4,785 and N participants=227)<sup>10</sup>, and eight novel relationships involved NEFL, ING4,

193 PAF, MENT, TMCC3, CRP, FAM20A and PEF1. Several of the markers for cognitive function

194 were identified in previous work relating Olink proteins to cognitive function (such as CPM)<sup>29</sup> and

work that characterised SOMAmer signatures of cognitive decline and incident Alzheimer's disease
(such as SVEP1)<sup>8</sup>. No studies have performed SOMAmer-based, whole proteome PheWAS studies
of the brain imaging and cognitive score traits we have profiled in a heathy ageing population that
were not enriched for neurodegenerative diseases. However, replication of associations from several
studies <sup>9,29,30</sup> was found for a small subset of associations (Supplementary Table 19).

### 200 Integration of the brain health proteome with our pQTM dataset

Differential DNAm signatures were explored for the 191 protein markers that had  $P < 3.5 \times 10^{-4}$  in 201 202 associations with either cognitive scores, brain imaging measures or APOE e4 status in the protein 203 PheWAS. Of the 191 proteins, 17 had pQTMs in the fully-adjusted MWAS. Higher levels of 15 of 204 these proteins were associated with poorer brain health, while AMY2A and CST5 were associated 205 with more favourable brain health. There were a total of 35 pQTMs involving 31 unique CpGs that 206 were located within 20 distinct genes (Supplementary Table 20), with 15 trans (Fig. 5) and 20 cis 207 associations. All pQTMs were previously unreported. The 20 cis pQTMs involved the levels of 208 CHI3L1, IL18R1, SIGLEC5, OLFM2, UGDH, CRHBP, AMY2A and CFHR1 proteins. The trans 209 pQTMs involved the levels of SCUBE1, RBL2, TNFRSF1B, CST5, HEXB, ACY1, CRTAM, 210 SMPD1 and RBP5 proteins.

Of the 20 cis pQTMs, 11 involved CpGs in different genes to the protein-coding gene on the same chromosome, whereas the remaining 9 pQTMs involved CpGs located within the protein-coding gene. Several CpG sites were associated with multiple protein levels in the *trans* pQTMs (Fig. 5). DNAm at site cg06690548 in the *SLC7A11* gene was associated with RBP5, ACY1 and SCUBE1 levels. The cg11294350 site in the *CHPT1* gene was associated with HEXB and SMPD1 levels. The cg07839457 site in the NLRC5 gene was associated with the levels of CRTAM and TNFRSF1B. There was also a protein that had several *trans* associations with multiple CpG sites; pQTMs were

identified between circulating RBL2 levels and cg01132052, cg0539861, cg18487916, cg27294008
and cg18404041, within the *NEK4/ITIH3/ITIH1* gene region of chromosome 3.

#### 220 Functional mapping of neurological pQTMs

- 221 A lookup that integrated information from the GoDMC and eQTLGen databases assessed whether
- 222 pQTMs were partially driven by an underlying genetic component. This identified methylation
- quantitative trait loci (mQTLs) for CpGs that were associated with CHI3L1, IL18R1 and SIGLEC5
- and were also expression quantitative trait loci (eQTLs) for the respective protein levels
- 225 (Supplementary Table 20). Further visual inspection of the distributions for the 35 pQTMs indicated
- that trimodal distributions suggestive of unaccounted SNP effects were present for CpGs
- involved in seven of the pQTMs (Supplementary Fig. 12).
- Tissue expression profiles for the 33 genes that were linked to either CpGs or proteins in the 35

neurological pQTMs are summarised in Supplementary Fig. 13. Gene set enrichment for these 33

230 genes identified enrichment for immune effector pathways in a subset of 11 genes, whereas a cluster

- of four genes (SMPD1, HEXB, AMY2A and AMY2B) were enriched for amylase and hydrolase
- activity (Supplementary Fig. 14).
- 233 Of the 35 pQTMs, seven had CpGs that were located in either a CpG Shore or Shelf position and

there were 13 that were located either 1500 bp or 200 bp from the TSS of the protein-coding gene

- (Supplementary Table 20). Fifteen pQTMs involved CpGs that were located in the gene body and 7
- were located in either the first exon or UTR regions (Supplementary Table 20).
- 237 Promoter-capture Hi-C and ChIP-sequencing integration was used to assess the interactions and
- chromatin states of our pQTMs and associated CpG loci. This analysis focused on 11 of the 20 *cis*
- pQTMs that involved CpGs on the same chromosome as the protein-coding gene, but were located in
- a different gene. Mapping information is presented for the seven proteins involved in these pQTMs

241	in Supplementary Figs. 15-21. In all instances, we found evidence of spatial co-localisation of these
242	genes using promoter-capture Hi-C data from brain hippocampal tissue. We attempted to
243	contextualise these sites further with ChIP-seq (ENCODE project) analyses of active chromatin
244	marks H3K27ac and H3K4me1 and repressive chromatin H3K4me3 and H3K27me3 in both
245	peripheral blood mononuclear cells (PBMCs) and brain hippocampus. ChIP-seq data suggested that
246	in many instances there were shared regulatory regions that existed across both blood and
247	hippocampal samples that were hubs for local promoter interactions. For example, promoter loops
248	were found linking the S100Z and CRHBP genes, with a signature of activating (H3Kme1 and
249	H3K27ac) and silencing (H3k27me and H3K4me3) marks (normally considered bivalent chromatin)
250	that may form the basis for shared regulation of this gene locus.

. . . . .

-- -

### 251 **Discussion**

252 We have conducted a large-scale integration of the circulating proteome with indicators of brain 253 health and blood-based DNA methylation. We characterised 191 protein markers that were 254 associated with either brain imaging measures, cognitive scores or APOE e4 status in an ageing 255 population. We also report methylome-wide characterisations for the SOMAscan<sup>®</sup> panel V.4 (4,058 256 protein measurements) in a nested subset of this population. By integrating these datasets, we 257 uncovered 35 methylation signatures for 17 protein markers of brain health. We delineated pQTM 258 CpGs that had evidence of underlying genetic influence and characterised the potential for chromatin 259 interactions for genes involved in *cis* pQTMs. As this population consists of older individuals that 260 were not enriched for neurodegenerative diseases, the markers we identify are likely indicators of 261 healthy brain ageing.

Many of the 191 proteins identified in the protein PheWAS were part of inflammatory clusters with shared functions in acute phase response, complement cascade activity, innate immune activity and cytokine pathways. Tissue expression analyses suggested that a large proportion of the 191 protein

265 markers were not expressed in the brain; this supports work suggesting that sustained peripheral inflammation influences general brain health <sup>3132</sup> and accelerates cognitive decline <sup>8,33–35</sup>. However, a 266 subset of proteins were expressed in the central nervous system. Given that leakage at the blood-267 brain-barrier interface has been hallmarked as a part of healthy brain ageing <sup>36,37</sup>, there is a 268 possibility that brain-derived proteins may enter the bloodstream as biomarkers. SLIT and NTRK 269 270 Like Family Member 1 (SLITRK1), Neurocan (NCAN) and IgLON family member 5 (IGLON5) 271 were examples of proteins expressed in brain for which higher levels associated with either larger 272 grey matter volume, larger whole brain volume, or higher general fractional anisotropy. SLITRK1 273 localises at excitatory synapses and regulates synapse formation in hippocampal neurons <sup>38</sup>. 274 Neurocan (NCAN) is a component of neuronal extracellular matrix and is linked to neurite growth <sup>39</sup>. 275 IGLON5 has been implicated in maintenance of blood-brain-barrier integrity and an anti-IGLON5 antibody disease involves the deterioration of cognitive health <sup>40</sup>. Taken together, the protein markers 276 277 identified in the PheWAS may, therefore, reflect pathways that could be targeted to improve brain 278 health.

279 Integration of our fully-adjusted protein MWAS dataset revealed 35 associations between DNAm and 17 protein markers of brain health (Fig. 6; Supplementary Table 20). All 35 associations were 280 281 novel. While this study is focused on blood DNAm – limiting generalisation to brain DNAm – many 282 of the 35 pQTMs involved CpGs and proteins that have been previously implicated in neurological 283 processes. DNAm at site cg06690548 (located in the SLC7A11 gene) was of particular interest; 284 differential DNAm at this CpG in blood has been identified as a causal candidate for Parkinson's 285 disease (N > 900 cases and N > 900 controls)  $^{41}$ . Xc- is the cystine-glutamate antiporter encoded by 286 SLC7A11, which facilitates glutamatergic transmission, oxidative stress defence and microglial response in the brain <sup>4243</sup> and is a target for the neurodegeneration-associated environmental 287 neurotoxin  $\beta$ -methylamino-L-alanine <sup>41</sup>. Analyses in the wider Generation Scotland cohort suggests 288 that cg06690548 is a site associated with alcohol consumption <sup>44</sup>. The proteins associated with 289

290 cg06690548 in the subset of this cohort we assessed (ACY1, SCUBE1 and RBP5) have known links to liver function <sup>45–47</sup>. DNAm at cg06690548 in blood has also been recently implicated in the largest 291 MWAS of amyotrophic lateral sclerosis (ALS) to date (6,763 cases, 2,943 controls)<sup>48</sup>. Given that 292 293 ACY1, SCUBE1 and RBP5 were markers for either lower processing speed and higher relative brain age, the CpG sites we identify in this study – such as cg06690548 – may be important plasma 294 295 markers for mediation of environmental risk on brain health that merit further exploration. cg06690548 lies within the first intron of *SLC7A11*<sup>41</sup>, indicating that this site is of potential 296 297 functional significance.

298 The presence of *NLRC5* and various other inflammatory proteins in our neurological protein pQTMs 299 suggests that the methylome may capture an inflammatory component of brain health. Many of the 300 genes corresponding to CpGs and proteins involved in the 35 pQTMs were enriched for immune 301 effector processes and were not expressed in brain. However, some markers did show evidence for 302 brain-specific expression, such as acid sphingomyelinase (SMPD1) and Hexosaminidase Subunit 303 Beta (HEXB). The HEXB and SMPD1 proteins associated with DNAm at cg11294350 (in the 304 *CHPT1* gene), are involved in neuronal lipid degradation in the brain and have been associated with the onset of a range of neurodegenerative conditions <sup>49–52</sup>. RBL2 is another protein that had partial 305 306 expression signals across brain regions; the NEK4/ITIH3/ITIH1 region was the location for five 307 CpGs with differential DNAm linked to RBL2 levels. This region is implicated in schizophrenia and bipolar disorder by several large-scale, genome-wide association studies (GWAS)<sup>53-56</sup>. Similarly, 308 309 the *RBL2* locus has been associated with intelligence, cognitive function and educational attainment in GWAS (n > 260,000 individuals)  $^{33,57,58}$ . 310

Given that this study utilised CpGs from the Illumina EPIC array, 15 of the 31 unique CpGs did not have mQTL characterisations in public databases, which primarily comprise results from the earlier 450K array. However, our plots showing pQTM associations suggested that for several CpGs (such

as cg11294350 that associated with SMPD1 and HEXB), there may be a partial genetic component influencing DNAm. As mQTLs tend to explain 15-17% of the additive genetic variance of DNAm <sup>59</sup>, it is possible that the signals we isolate in these instances are partially driven by genetic loci, but are also likely driven by unmeasured environmental and biological influences. In the case of SIGLEC5, IL18R1 and CHI3L, mQTLs were identified that were also eQTLs, providing evidence that mQTLs for these CpG sites were possible regulators of protein expression.

Integration of promoter-capture Hi-C chromatin interaction and ChIP-seq databases <sup>60</sup> provided 320 321 evidence for long-range interaction relationships for *cis* pQTMs with CpGs in different gene regions 322 that are proximal to the protein-coding gene of interest. This suggests that in such instances, the 323 pQTMs may reflect regulatory relationships in the 3-dimensional genomic neighbourhood. The 324 pQTMs therefore direct us towards pathways that can be tested in experimental constructs. Positional 325 information suggested that many CpGs involved in neurological pQTMs lay within 1500 bp of the 326 TSS of the respective protein-coding gene. While positional information of CpGs is thought to infer 327 whether DNAm is likely to play a role in the expression regulation of nearby genes, this is still somewhat disputed. Some studies suggest that transcription factors regulate DNAm<sup>61</sup> and 328 differential methylation at gene body locations predicts dosage of functional genes <sup>62</sup>. Additionally, 329 330 the DNAm signatures of proteins we quantify represent widespread differences across blood cells 331 that are related to circulating protein levels and are therefore not derived from the same cell-types as 332 proteins. Despite this limitation, previous work supports DNAm scores for proteins as useful markers 333 of brain health, suggesting there is merit in integrating DNAm signatures of protein levels in disease stratification <sup>18</sup>. 334

Our study has several limitations. First, though full replication of our results was not possible, our replication of pQTMs identified by Zaghlool *et al* <sup>14</sup> reinforces inflammation signalling as intrinsic to the methylome signature of blood proteins. This also suggests that pQTMs may be common across

338 ancestries. Second, we observed a substantial inflation for PAPPA and PRG3 proteins. While 339 comprehensive adjustment for estimated immune cells was performed and the remainder of CpGs 340 involved in pQTMs did not show high correlations (Supplementary Fig. 2), concurrently measured 341 blood components such as haemoglobin, red blood cells and platelets were not available. Future studies should seek to resolve signals with more detailed blood-cell phenotyping and immune cell 342 estimates <sup>63</sup>. Third, 89% of the proteins identified in our protein PheWAS did not have epigenetic 343 344 pQTMs; this may be due to 1) the presence of pathways relating to neurological disease that are not 345 reflected by blood immune cell DNAm, 2) underpowered analyses, or 3) the presence of indirect 346 associations that are not captured by our MWAS approach. Fourth, the extent of non-specific and cross-aptamer binding with SOMAmer technology has not been fully resolved <sup>64</sup>. Fifth, there are 347 348 likely unknown genetic influences on pQTMs. Further characterisation of pQTLs and advances in multi-omic modelling techniques<sup>15</sup> will aid in the separation of genetic and environmental 349 350 influences on epigenetic signatures. Sixth, differences in blood and brain DNAm and pQTLs are 351 emerging; these indicate that blood-based markers may not fully align to biology of brain degeneration <sup>65,66</sup>. However, our ChIP-seq analysis of chromatin regulation suggested that some 352 353 regulatory states may persist between blood and brain. Seventh, profiling DNAm signatures alone 354 cannot capture the full role of the epigenome in brain health. Integration of more diverse epigenetic 355 markers will be critical to further resolve these relationships. Finally, though we have incorporated a 356 wide portfolio of brain health measures, we recognise that these are not extensive. Increasing 357 triangulation across modalities, as we have shown here, will be useful in identifying candidate 358 markers.

In conclusion, by integrating epigenetic and proteomic data with cognitive scoring, brain morphology and *APOE* e4 status, we identify 191 protein markers of brain health. We characterise DNAm signatures for all 4,058 proteins included in the study, uncovering 35 associations between differential DNAm and the levels of 17 of the protein markers of brain health outcomes. These data

identify candidate targets for the preservation of brain health and may inform risk stratificationapproaches.

## 365 Methods

#### **366 The Generation Scotland sample population**

367 The Stratifying Resilience and Depression Longitudinally (STRADL) cohort used in this study is a 368 subset of N=1,188 individuals from Generation Scotland: The Scottish Family Health Study (GS). 369 Generation Scotland constitutes a large, family-structured, population-based cohort of >24,000 individuals from Scotland 67. Individuals were recruited to GS between 2006 and 2011. During a 370 371 clinical visit detailed health, cognitive, and lifestyle information was collected in addition to 372 biological samples. Of the 21,525 individuals contacted for participation, N=1,188 completed additional health assessments and biological sampling approximately five years after GS baseline <sup>68</sup>. 373 374 Of these, N=1,065 individuals had proteomic data available and N=778 of these had DNAm data 375 available. Supplementary Table 2 summarises the demographic characteristics across the two 376 groups, with descriptive statistics for phenotypes.

#### 377 Proteomic measurement

378 SOMAscan<sup>®</sup> V.4 technology was used to quantify plasma protein levels. This aptamer-based assay 379 facilitates the simultaneous measurements of multiple SOMAmers (Slow Off-rate Modified Aptamers) <sup>69</sup>. SOMAmers were processed for 1,065 individuals from the STRADL subset of GS. 380 381 Briefly, binding between plasma samples and target SOMAmers was achieved during incubation and 382 quantification was recorded using a fluorescent signal on microarrays. Quality control steps included 383 hybridization normalization, signal calibration and median signal normalization to control for inter-384 plate variation. Full details of quality control stages are provided in Supplementary Methods. In the 385 final dataset, 4,235 SOMAmer epitope measures were available in 1,065 individuals and these

corresponded to 4,058 unique proteins (classified by common Entrez gene names). Supplementary
Table 2 provides annotation information for the 4,235 SOMAme measurements that were available.

#### 388 **DNAm measurement**

389 Measurements of blood DNAm in the STRADL subset of GS subset were processed in two sets on 390 the Illumina EPIC array using the same methodology as those collected in the wider Generation Scotland cohort. Quality control details have been reported previously <sup>70–72</sup> and further details are 391 392 provided in Supplementary Methods. Briefly, samples were removed if there was a mismatch 393 between DNAm-predicted and genotype-based sex and all non-specific CpG and SNP probes (with 394 allele frequency > 5%) were removed from the methylation file. Probes which had a beadcount of 395 less than 3 in more than 5% of samples and/or probes in which >1% of samples had a detection 396 P>0.01 were excluded. After quality control, 793,706 and 773,860 CpG were available in sets 1 and 397 2, respectively. These sets were truncated to include a total of 772,619 common probes and were 398 joined together for use in the MWAS, with 476 individuals included in set 1 and 298 individuals in 399 set 2. DNAm-specific technical variables (measurement batch and set) were adjusted in all MWAS 400 and PheWAS models.

#### 401 **Phenotypes in Generation Scotland**

402 All phenotypes in Generation Scotland MWAS and PheWAS samples are summarised in Supplementary Table 2. An epigenetic score for smoking exposure, EpiSmokEr<sup>73</sup> was calculated 403 for all individuals with DNAm. The meffil <sup>74</sup> implementation of the Houseman method was used to 404 calculate estimated white blood cell (WBC) proportions for Sets 1 and 2. Blood reference panels 405 406 were sourced from Reinius et al<sup>75</sup>. The 'blood gse35069 complete' panel was used to imputed 407 measures for Monocytes, Natural Killer cells, Bcells, Granulocytes, CD4<sup>+</sup>T cells and CD8<sup>+</sup>T cells. 408 Eosinophil and Neutrophil estimates were also sourced through the 'blood gse35069' panel. Body 409 mass index (body weight in kilograms, divided by squared height in metres) was available for all

individuals, alongside depression status (defined using a research version of the Structured Clinical Interview for DSM disorders (SCID) assessment), which was coded as a binary variable of no history of depression (0) or lifetime episode of depression (1). Five individuals did not have depression status information and were excluded from MWAS and PheWAS analyses, where appropriate. *APOE* e4 status was available for 1,050 individuals. *APOE* e4 status was coded as a numeric variable (e2e2 = 0, e2e3 = 0, e3e3 = 1, e3e4 = 2, e4e4 = 2). Fifteen e2e4 individuals were excluded due to small sample size.

417 Scores from five cognitive tests (Supplementary Fig. 4; Supplementary Table 2) measured at the 418 clinic visit for the STRADL subset of GS were considered. Full details for the specific scores has been detailed previously <sup>68</sup> and further details can be found in Supplementary Methods. Briefly, 419 420 these included the Wechsler Logical Memory Test (maximum possible score of 50), the Wechsler 421 Digit Symbol Substitution Test (maximum possible score of 133), the verbal fluency test (based on 422 the Controlled Oral Word Association task), the Mill Hill Vocabulary test (maximum possible score 423 of 44) and the Matrix Reasoning test (maximum possible score of 15). Outliers were defined as 424 scores >3.5 standard deviations above or below the mean and were removed prior to analysis. The 425 first unrotated principal component combining logical memory, verbal fluency, vocabulary and digit 426 symbol tests was calculated as a measure of general cognitive ability ('g'). General fluid cognitive 427 ability ('gf') was extracted using the same approach, but with the vocabulary test (a crystallised measure of intelligence) excluded from the model. While highly similar to g, the gf score is 428 429 exclusive to measures such as memory and processing capability that are considered fluid. gf may 430 therefore be of greater relevance for assessing cognitive decline in ageing individuals.

The derived brain volume measures (Supplementary Fig. 5; Supplementary Table 2) were recorded
at two sites (Aberdeen and Edinburgh) <sup>68</sup>. Brain volume data included total brain volume (ventricle
volumes excluded), global grey matter volume, white matter hyperintensity volume and total

434 intracranial volume. Intracranial volume was treated as a covariate to adjust for head size in all tests 435 including brain volume associations. The derived global white matter integrity measures included global fractional anisotropy (gFA) and global mean diffusivity (gMD). The protocols applied to 436 derive the brain volume measures from T1-weighted scans, and white matter integrity measures from 437 diffusion tensor imaging (DTI) scans have been previously described <sup>35,68,76</sup> and additional details are 438 439 also provided in Supplementary Methods. Brain Age was estimated using the software package 440 'brainageR' (Version 2.1; DOI: 10.5281/zenodo.3476365, available at https://github.com/james-441 cole/brainageR), which uses machine learning and a large training set to predict age from wholebrain voxel-wise volumetric data derived from structural T1 images<sup>3</sup>. This estimate was regressed 442 443 on chronological age to produce a measure of Relative Brain Age (residuals from the linear model). 444 Outliers for all imaging variables were defined as measurements >3.5 standard deviations above or 445 below the mean and were removed prior to analysis.

#### 446 Phenome-wide association analyses

447 Prior to running protein PheWAS analyses, protein levels were transformed by rank-based inverse normalisation and scaled to have a mean of zero and standard deviation of 1. Models were run using 448 the lmekin function in the coxme R package <sup>77</sup>. This modelling strategy allows for mixed-effects 449 450 linear model structure with adjustment for relatedness between individuals. Models were run in the 451 maximum sample of 1,095 individuals, with the 4,235 protein levels as dependent variables and 452 phenotypes as independent variables. A random intercept was fitted for each individual and a kinship matrix was included as a random effect to adjust for relatedness. Age, sex (male = 1, reference 453 female = 0), numerical APOE e4 status variable (e2 = 0, e3 = 1, e4 = 2), cognitive and brain imaging 454 455 phenotypes were included as scaled predictors. Continuous variables were scaled to mean of zero and variance one. Diagnosis of depression (case = 1, reference control = 0) at the STRADL clinic 456 457 visit in GS was included as a covariate in all models, due to known selection bias for depression

.

. .

450	phenotypes in STRADE . Chine study site and protein ag group (storage time before proteonite
459	sequencing) were included as covariates in all models. Missing data were excluded from lmekin
460	models.

. . .

GTTD 1 DI 68 GU 1

- 461 Three regression models were considered. For the analyses with age and sex as the predictors of 462 interest, two coefficients ( $\beta$ 1 and  $\beta$ 2) were extracted.
- 463 Protein level ~ Intercept +  $\beta$ 1 age +  $\beta$ 2 sex + depression + study site + lag group + (1|individual) + 464 (1|kinship)
- For the analyses with one of cognitive scoring, *APOE* e4 status or non-volumetric brain imaging as the predictor of interest, the  $\beta$ 3 coefficient was extracted.

467 Protein level ~ Intercept + age + sex +  $\beta$ 3 phenotype + depression + study site + lag group + 468 (1|individual) + (1|kinship)

Finally, for the models with volumetric brain imaging measures as the predictor of interest the  $\beta$ 4 coefficient was extracted.

471 Protein level ~ Intercept + age + sex + β4 phenotype + depression + study site\*ICV + lag group +
472 edited + batch + (1|individual) + (1|kinship)

All analyses of brain volume measures included adjustment for intracranial volume and study site as
main effects, in addition to the interaction between these variables. ICV was used to account for head
size. Imaging data processing batch, and presence or absence of manual intervention during quality
control (edited) variables were also included as covariates, wherever appropriate.

P-values for all PheWAS models were calculated in R using effect size estimates (beta) and standard
errors (SE) as follows: pchisq((beta/SE)^2, 1, lower.tail=F). The Prcomp package <sup>78</sup> was used to
generate principal components for the 4,235 SOMAmer measurements (N=1,065). 143 components

explained >80% of the cumulative variance in protein levels (Supplementary Fig. 1 and Supplementary Table 3); these components were used to derive the PheWAS multiple testing adjustment threshold of  $P < 0.05 / 143 = 3.5 \times 10^{-4}$ . This method was chosen due to the presence of high intercorrelations within the protein data.

### 484 Epigenome-wide association study of protein levels

485 Prior to running the MWAS, protein levels for 774 individuals with complete phenotypic information were log transformed and regressed on age, sex, study site, lag group and 20 genetic principal 486 components (generated from multidimensional scaling of genotype data from the Illumina 610-487 488 Quadv1 array). Residuals from these models were then rank-based inverse normalised and taken 489 forward as protein level data. Methylation data were in M-value format and were pre-adjusted for age, sex, processing batch, methylation set, depression status <sup>73</sup> and known pOTL effects (from a 490 491 previous genome-wide association study of 4,034 SOMAmers targeting 3,622 proteins from Sun et al)  $^{24}$  in the basic MWAS. A second model further adjusted for estimated white blood cell 492 493 proportions (Monocytes, CD4<sup>+</sup>T cells, CD8<sup>+</sup>T cells, BCells, Natural Killer cells, Granulocytes and 494 Eosinophils). While Neutrophil estimates were available, they were excluded due to high correlation 495 (>95%) with Granulocyte proportions (Supplementary Fig. 22). Finally, the fully-adjusted model further regressed DNAm onto an epigenetic score for smoking, EpiSmokEr<sup>73</sup> and body mass index 496 497 (BMI).

Omics-data-based complex trait analysis (OSCA) <sup>79</sup> Version 0.41 was used to run EWAS analyses. Within OSCA, a genetic relationship matrix (GRM) was constructed for the STRADL population. A threshold of 0.05 was used to identify 120 individuals likely to be related based on their genetic similarity. For this reason, the MOA method was used to calculate associations between individual CpG sites and protein levels, with the addition of the GRM as a random effect to adjust for

relatedness between individuals <sup>79</sup>. CpG sites were the dependent variables and the 4,235 proteins
were the independent variables.

505 Five fully-adjusted models did not converge (NAGLU, CFHR2, DAP, MST1, PILRA) and were excluded. A threshold for multiple testing correction ( $P < 4.5 \times 10^{-10}$ ) was based on 143 independent 506 protein components with cumulative variance >80% (Supplementary Fig. 1 and Supplementary 507 Table 3) (P < 0.05/(143x772.619) CpGs). A more conservative threshold based on total number of 508 SOMAmers was also considered (P <  $0.05/(4,235x772,619) = 1.5x10^{-11}$ ) and is detailed in 509 510 Supplementary Tables 4-6. pQTMs were classified as *cis* if the CpG was on the same chromosome 511 as the protein-coding gene and fell within 10Mb of the transcriptional start site (TSS) of the protein 512 gene. pQTMs involving a CpG located on a different chromosome to the protein-coding gene, or 513 >10Mb from the TSS of the protein gene were classed as *trans*.

Circos plots were created with the circlize package (Version 0.4.12)<sup>80</sup>. BioRender.com was used to
create Figs. 1, 2, 3 and 6. All analyses were performed in R (Version 4.0)<sup>81</sup>.

#### 516 Functional mapping and tissue expression analyses

Functional mapping and annotation (FUMA)<sup>82</sup> gene set enrichment analyses were conducted for 517 genes corresponding to protein markers that were identified through the PheWAS study, in addition 518 519 to genes linked to either CpGs or proteins in the neurological pQTM subset. Protein-coding genes 520 were selected as the background set and ensemble v92 was used with a false discovery rate (FDR) 521 adjusted P < 0.05 threshold for gene set testing. For the genes corresponding to protein markers in the PheWAS a minimum overlapping number of genes was set to 3, whereas this was set to 2 for the 522 genes involved in neurological pQTMs for the purposes of visualisation. The STRING<sup>83</sup> database 523 524 was queried to build a protein interaction network based on all proteins that had associations in the PheWAS. mOTL and eOTL lookups were performed using the GoDMC <sup>59</sup> and eOTLGen databases 525

<sup>84</sup>, respectively. UCSC database searches were used to profile the positional information relating to
 CpGs in the pQTMs involving proteins associated with brain health.

528 Although inter-chromosomal chromatin interactions are unlikely to be stable and persistent, seven 529 proteins with *cis* pQTMs involving CpGs located intra-chromosomally to the proximal protein-530 coding gene were considered for ChIP-seq and promoter-capture Hi-C mapping to interrogate local 531 chromatin interactions and states that might form the basis for co-regulation of these loci. ChIP-seq data from peripheral blood mononuclear cells (PBMCs) and brain hippocampus were selected from 532 the ENCODE project <sup>86</sup>, with accession identifiers available in Supplementary Table 21. Processed 533 promoter-capture Hi-C data for brain hippocampal tissue was integrated from Jung et al, <sup>60</sup> and is 534 available at NCBI Geo with accession GSE86189. Data concerning both promoter-prometer 535 536 interactions and promoter-other interactions were concatenated and all regions subsequently visualised on the WashU epigenome browser 87. 537

#### 538 Ethics declarations

All components of GS received ethical approval from the NHS Tayside Committee on Medical Research Ethics (REC Reference Number: 05/S1401/89). GS has also been granted Research Tissue Bank status by the East of Scotland Research Ethics Service (REC Reference Number: 20/ES/0021), providing generic ethical approval for a wide range of uses within medical research.

### 543 Data availability

544 Datasets generated in this study are made available in Supplementary Tables. Source data are 545 provided with this paper.

546 Fully-adjusted MWAS summary statistics for protein levels are available through Zenodo [insert

547 details once accepted files are uploaded] and hosted on the MRC-IEU EWAS catalog [insert details

548 once accepted files are uploaded]  $^{25}$ .

- 549 A YouTube video summarising the findings of the study and detailing how to access files can be
- viewed at https://www.youtube.com/channel/UCxQrFFTIItF25YKfJTXuumQ.
- 551 The source datasets from the cohorts that were analysed during the current study are not publicly
- available due to them containing information that could compromise participant consent and
- 553 confidentiality. Data can be obtained from the data owners. Instructions for accessing Generation
- 554 Scotland data can be found here: <u>https://www.ed.ac.uk/generation-scotland/for-researchers/access</u>;
- the 'GS Access Request Form' can be downloaded from this site. Completed request forms must be
- sent to <u>access@generationscotland.org</u> to be approved by the Generation Scotland Access
- 557 Committee.

#### 558 Code availability

All R code used in this study is available with open access at the following Gitlab repository:

560 <u>https://gitlab.com/dannigadd/epigenome-and-phenome-wide-study-of-brain-health-outcomes/-</u>

561 <u>/tree/main</u>

### 562 Acknowledgements

This research was funded in whole, or in part, by the Wellcome Trust [104036/Z/14/Z, 563 564 108890/Z/15/Z, 221890/Z/20/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this 565 566 submission. D.A.G. and R.F.H. are supported by funding from the Wellcome Trust 4-year PhD in Translational Neuroscience-training the next generation of basic neuroscientists to embrace clinical 567 568 research [108890/Z/15/Z]. R.I.M is supported by funding from the Wellcome Trust PhD for 569 clinicians, Edinburgh Clinical Academic Track for Veterinary Surgeons. D.L.Mc.C. and R.E.M. are 570 supported by Alzheimer's Research UK major project grant ARUK-PG2017B-10. R.E.M is supported by Alzheimer's Society major project grant AS-PG-19b-010. Generation Scotland 571

572 received core support from the Chief Scientist Office of the Scottish Government Health Directorates 573 (CZD/16/6) and the Scottish Funding Council (HR03006). Genotyping and DNA methylation 574 profiling of the GS samples was carried out by the Genetics Core Laboratory at the Clinical Research 575 Facility, University of Edinburgh, Scotland and was funded by the Medical Research Council UK and the Wellcome Trust (Wellcome Trust Strategic Award "STratifying Resilience and Depression 576 577 Longitudinally" ([STRADL; Reference 104036/Z/14/Z]). Proteomic analyses in STRADL were 578 supported by Dementias Platform UK (DPUK). DPUK funded this work through core grant support 579 from the Medical Research Council [MR/L023784/2]. C.H. is supported by an MRC University Unit 580 Programme Grant MC UU 00007/10 (OTL in Health and Disease). L.S. is funded by DPUK 581 through MRC (grant no. MR/L023784/2) and the UK Medical Research Council Award to the 582 University of Oxford (grant no. MC\_PC\_17215). L.S. also received support from the NIHR 583 Biomedical Research Centre at Oxford Health NHS Foundation Trust.

584 S.R.C is supported by the Medical Research Council (MR/R024065/1), a National Institutes of 585 Health research grant (R01AG054628) and a Sir Henry Dale Fellowship jointly funded by the 586 Wellcome Trust and the Royal Society (Grant Number 221890/Z/20/Z).

JDS is funded by MRC grants MR/S010351/1, MR/W002566/1 and MR/W002388/1. JMW is supported by the UK Dementia Research Institute which receives its funding from DRI Ltd, funded by the UK Medical Research Council, Alzheimer's Society and Alzheimer's Research UK. EB is supported by Stroke Association/BHF/Alzheimer's Society 'Rates Risks and Routes to Reduce Vascular Dementia' (R4VaD) Priority Programme Award in Vascular Dementia (16 VAD 07).

The authors acknowledge the work of Rebecca Madden, Marco Squillace and Laura Klinkhamerwho aided in the quality control of volumetric brain imaging data.

## 594 Author contributions

- 595 D.A.G., and R.E.M., were responsible for the conception and design of the study. D.A.G. carried out
- the data analyses. D.A.G., and R.E.M., drafted the article. S.R.C., and H.W., advised on
- 597 methodology. R.F.H., and D.L.Mc., contributed to methodology and data analyses. R.I.McG., S.M.,
- 598 R.M.W., L.S., D.L.Mc., R.M.W., A.C., A.N.H., C.H., K.L.E., D.J.P., H.W., A.M.M., and S.R.C.,
- 599 contributed to data methylation and proteomic data collection and preparation. A.S., M.C.B.,
- 600 M.A.H., E.V.B., J.D.S., S.X., C.G., and J.M.W processed the brain imaging data. D.A.O., G.M.T.,
- and C.R., provided scientific counsel. T.C., and N.R., consulted on chromatin analyses. R.E.M.,
- supervised the project. All authors read and approved the final manuscript.

### 603 **Competing interests**

- 604 R.E.M has received a speaker fee from Illumina and is an advisor to the Epigenetic Clock
- 605 Development Foundation. A.M.M has previously received speaker's fees from Illumina and Janssen
- and research grant funding from The Sackler Trust. R.F.H. has received consultant fees from
- 607 Illumina. All other authors declare no competing interest.

### 608 Materials and correspondence

- All correspondence and material requests should be sent to Dr Riccardo Marioni at
- 610 riccardo.marioni@ed.ac.uk.

## 611 **References**

- 1. Ly, M. *et al.* Late-life depression and increased risk of dementia: a longitudinal cohort study.
- 613 *Transl. Psychiatry 2021 111* **11**, 1–10 (2021).
- 614 2. Shi, Y. & Wardlaw, J. M. Update on cerebral small vessel disease: a dynamic whole-brain
- 615 disease. *Stroke Vasc. Neurol.* **1**, 83–92 (2016).
- Biondo, F. *et al.* Brain-age predicts subsequent dementia in memory clinic patients. *medRxiv*2021.04.03.21254781 (2021) doi:10.1101/2021.04.03.21254781.
- 4. Cox, S. R., Ritchie, S. J., Fawns-Ritchie, C., Tucker-Drob, E. M. & Deary, I. J. Structural

brain imaging correlates of general intelligence in UK Biobank. *Intelligence* 76, 101376
(2019).

- 5. Corley, J. *et al.* Epigenetic signatures of smoking associate with cognitive function, brain
  structure, and mental and physical health outcomes in the Lothian Birth Cohort 1936. *Transl. Psychiatry* 9, (2019).
- 6. Stillman, C. M., Weinstein, A. M., Marsland, A. L., Gianaros, P. J. & Erickson, K. I. Body–
   Brain Connections: The Effects of Obesity and Behavioral Interventions on Neurocognitive
   Aging. *Front. Aging Neurosci.* 9, 115 (2017).
- 627 7. Livingston, G. *et al.* Dementia prevention, intervention, and care: 2020 report of the Lancet
  628 Commission. *The Lancet* vol. 396 413–446 (2020).
- Lindbohm, J. V *et al.* Association of plasma proteins with rate of cognitive decline and
  dementia: 20-year follow-up of the Whitehall II and ARIC cohort studies. *medRxiv*2020.11.18.20234070 (2020) doi:10.1101/2020.11.18.20234070.
- 632 9. Walker, K. A. *et al.* Large-scale plasma proteomic analysis identifies proteins and pathways

633		associated with dementia risk. Nat. Aging 1, 473–489 (2021).
634	10.	Sebastiani, P. et al. A serum protein signature of APOE genotypes in centenarians. Aging Cell
635		<b>18</b> , e13023 (2019).
636	11.	Berson, A., Nativio, R., Berger, S. L. & Bonini, N. M. Epigenetic Regulation in
637		Neurodegenerative Diseases. Trends Neurosci. 41, 587 (2018).
638	12.	Al-Mahdawi, S., Virmouni, S. A. & Pook, M. A. The emerging role of 5-
639		hydroxymethylcytosine in neurodegenerative diseases. Front. Neurosci. 8, 397 (2014).
640	13.	Lea, A. J. et al. Genome-wide quantification of the effects of DNA methylation on human
641		gene regulation. <i>Elife</i> eLife 2018;7:e37513 (2018) doi:10.7554/eLife.37513.
642	14.	Zaghlool, S. B. et al. Epigenetics meets proteomics in an epigenome-wide association study
643		with circulating blood plasma protein traits. Nat. Commun. 11, 15 (2020).
644	15.	Hillary, R. F. et al. Multi-method genome- And epigenome-wide studies of inflammatory
645		protein levels in healthy older adults. Genome Med. 12, 60 (2020).
646	16.	Hillary, R. F. et al. Genome and epigenome wide studies of neurological protein biomarkers in
647		the Lothian Birth Cohort 1936. Nat. Commun. 10, 3160 (2019).
648	17.	Conole, E. L. S. et al. DNA Methylation and Protein Markers of Chronic Inflammation and
649		Their Associations With Brain and Cognitive Aging. <i>Neurology</i> <b>97</b> , e2340–e2352 (2021).
650	18.	Gadd, D. A. et al. Epigenetic scores for the circulating proteome as tools for disease
651		prediction. <i>Elife</i> <b>11</b> , (2022).
652	19.	Hillary, R. F. et al. Genome and epigenome wide studies of plasma protein biomarkers for
653		Alzheimer's disease implicate TBCA and TREM2 in disease risk. medRxiv

654 2021.06.07.21258457 (2021) doi:10.1101/2021.06.07.21258457.

- 655 20. Sun, B. B. *et al.* Genomic atlas of the human plasma proteome. *Nature* **558**, 73–79 (2018).
- 656 21. Houseman, E. A. et al. DNA methylation arrays as surrogate measures of cell mixture
- distribution. *BMC Bioinformatics* **13**, 86 (2012).
- McCartney, D. L. *et al.* Epigenetic signatures of starting and stopping smoking. *EBioMedicine*37, 214–220 (2018).
- McCartney, D. L. *et al.* Epigenetic prediction of complex traits and death. *Genome Biol.* 19, 136 (2018).
- 662 24. Sun, B. B. *et al.* Genomic atlas of the human plasma proteome. *Nature* **558**, 73–79 (2018).
- MRC-IEU. The MRC-IEU catalog of epigenome-wide association studies. Avaialable at:
  http://www.ewascatalog.org. Accessed April 2021. (2021).

Saffari, A. *et al.* Estimation of a significance threshold for epigenome-wide association
studies. 42, 22–23 (2017).

- Ferkingstad, E. *et al.* Large-scale integration of the plasma proteome with genetics and
  disease. *Nat. Genet.* 2021 5312 53, 1712–1721 (2021).
- 28. Lehallier, B. *et al.* Undulating changes in human plasma proteome profiles across the lifespan. *Nat. Med.* 25, 1843–1850 (2019).
- Harris, S. E. *et al.* Neurology-related protein biomarkers are associated with cognitive ability
  and brain volume in older age. *Nat. Commun.* 11, 1–12 (2020).

673 30. Shi, L. *et al.* Identification of plasma proteins relating to brain neurodegeneration and vascular

674 pathology in cognitively normal individuals. *Alzheimer's Dement. Diagnosis, Assess. Dis.* 

675	Monit.	13,	(2021).
-----	--------	-----	---------

676	31.	Jefferson, A. L. et al. Inflammatory biomarkers are associated with total brain volume: The
677		Framingham Heart Study. Neurology 68, 1032–1038 (2007).

32. Janowitz, D. *et al.* Inflammatory markers and imaging patterns of advanced brain aging in the

679 general population. *Brain Imaging Behav.* **14**, 1108–1117 (2020).

- 680 33. Lee, J. J. *et al.* Gene discovery and polygenic prediction from a genome-wide association
- study of educational attainment in 1.1 million individuals. *Nat. Genet.* **50**, 1112–1121 (2018).
- 682 34. Conole, E. L. S. *et al.* An epigenetic proxy of chronic inflammation outperforms serum levels
- as a biomarker of brain ageing. medRxiv. (2020)
- 684 doi:https://doi.org/10.1101/2020.10.08.20205245.
- 685 35. C, G. *et al.* Structural brain correlates of serum and epigenetic markers of inflammation in
  686 major depressive disorder. *Brain. Behav. Immun.* 92, 39–48 (2021).
- Banks, W. A., Reed, M. J., Logsdon, A. F., Rhea, E. M. & Erickson, M. A. Healthy aging and
  the blood–brain barrier. doi:10.1038/s43587-021-00043-5.
- Montagne, A. *et al.* Blood-Brain Barrier Breakdown in the Aging Human Hippocampus. *Neuron* 85, 296 (2015).
- 38. Beaubien, F., Raja, R., Kennedy, T. E., Fournier, A. E. & Cloutier, J. F. Slitrk1 is localized to
- 692 excitatory synapses and promotes their development. *Sci. Reports 2016 61* **6**, 1–10 (2016).
- Schmidt, S., Arendt, T., Morawski, M. & Sonntag, M. Neurocan Contributes to Perineuronal
  Net Development. *Neuroscience* 442, 69–86 (2020).
- 695 40. Madetko, N. et al. Anti-IgLON5 Disease The Current State of Knowledge and Further

696		Perspectives. Front. Immunol. 0, 777 (2022).
697	41.	Vallerga, C. L. et al. Analysis of DNA methylation associates the cystine-glutamate antiporter
698		SLC7A11 with risk of Parkinson's disease. Nat. Commun. 11, 1–10 (2020).
699	42.	Fournier, M. et al. Implication of the glutamate-cystine antiporter xCT in schizophrenia cases
700		linked to impaired GSH synthesis. npj Schizophr. 3, 1–7 (2017).
701	43.	Mesci, P. et al. System xC- is a mediator of microglial function and its deletion slows
702		symptoms in amyotrophic lateral sclerosis mice. Brain 138, 53-68 (2015).
703	44.	Lohoff, F. W. <i>et al.</i> Epigenome-wide association study of alcohol consumption in $N = 8161$
704		individuals and relevance to alcohol use disorder pathophysiology: identification of the
705		cystine/glutamate transporter SLC7A11 as a top target. Mol. Psychiatry (2021)
706		doi:10.1038/S41380-021-01378-6.
707	45.	Wood, G. C. et al. A multi-component classifier for nonalcoholic fatty liver disease (NAFLD)
708		based on genomic, proteomic, and phenomic data domains. Sci. Rep. 7, (2017).
709	46.	Zhuang, J., Deane, J. A., Yang, R. B., Li, J. & Ricardo, S. D. SCUBE1, a novel developmental
710		gene involved in renal regeneration and repair. Nephrol. Dial. Transplant. 25, 1421–1428
711		(2010).
712	47.	Ho, J. C. Y. et al. Down-regulation of retinol binding protein 5 is associated with aggressive
713		tumor features in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 133, 929–936 (2007).
714	48.	Hop, P. J. et al. Genome-wide study of DNA methylation shows alterations in metabolic,
715		inflammatory, and cholesterol pathways in ALS. Sci. Transl. Med. 14, 36 (2022).
716	49.	Park, M. H., Jin, H. K. & Bae, J. sung. Potential therapeutic target for aging and age-related

717		neurodegenerative diseases: the role of acid sphingomyelinase. Exp. Mol. Med. 52, 380-389
718		(2020).
719	50.	Lee, J. K. et al. Acid sphingomyelinase modulates the autophagic process by controlling
720		lysosomal biogenesis in Alzheimer's disease. J. Exp. Med. 211, 1551–1570 (2014).
721	51.	Kyrkanides, S. <i>et al.</i> Conditional expression of human $\beta$ -hexosaminidase in the neurons of
722		Sandhoff disease rescues mice from neurodegeneration but not neuroinflammation. J.
723		Neuroinflammation 9, 186 (2012).
724	52.	Bley, A. E. et al. Natural history of infantile G M2 gangliosidosis. Pediatrics 128, e1233
725		(2011).
726	53.	Hamshere, M. L. et al. Genome-wide significant associations in schizophrenia to ITIH3/4,
727		CACNA1C and SDCCAG8, and extensive replication of associations reported by the
728		Schizophrenia PGC. Mol. Psychiatry 18, 708–712 (2013).
729	54.	Witt, S. H. et al. Investigation of manic and euthymic episodes identifies state-and trait-
730		specific gene expression and stab1 as a new candidate gene for bipolar disorder. Transl.
731		<i>Psychiatry</i> <b>4</b> , 426 (2014).
732	55.	Ripke, S. et al. Genome-wide association study identifies five new schizophrenia loci. Nat.
733		<i>Genet.</i> <b>43</b> , 969–978 (2011).
734	56.	Sklar, P. et al. Large-scale genome-wide association analysis of bipolar disorder identifies a
735		new susceptibility locus near ODZ4. Nat. Genet. 43, 977-985 (2011).
736	57.	Davies, G. et al. Study of 300,486 individuals identifies 148 independent genetic loci
737		influencing general cognitive function. Nat. Commun. 9, 1–16 (2018).

- 58. Savage, J. E. et al. Genome-wide association meta-analysis in 269,867 individuals identifies
- new genetic and functional links to intelligence. *Nat. Genet.* **50**, 912–919 (2018).
- 59. Min, J. L. *et al.* Genomic and phenotypic insights from an atlas of genetic effects on DNA
- 741 methylation. *Nat. Genet.* **53**, 1311–1321 (2021).
- Jung, I. *et al.* A Compendium of Promoter-Centered Long-Range Chromatin Interactions in the
  Human Genome. *Nat. Genet.* 51, 1442 (2019).
- 61. Héberlé, É. & Bardet, A. F. Sensitivity of transcription factors to DNA methylation. *Essays Biochem.* 63, 727 (2019).
- 62. Arechederra, M. *et al.* Hypermethylation of gene body CpG islands predicts high dosage of

functional oncogenes in liver cancer. *Nat. Commun. 2018 91* **9**, 1–16 (2018).

- Salas, L. A. *et al.* Enhanced cell deconvolution of peripheral blood using DNA methylation
  for high-resolution immune profiling. *Nat. Commun. 2022 131* 13, 1–13 (2022).
- Pietzner, M. *et al.* Genetic architecture of host proteins involved in SARS-CoV-2 infection. *Nat. Commun.* 11, 6397 (2020).
- Yang, C. *et al.* Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins
  implicated in neurological disorders. *Nat. Neurosci.* 2021 249 24, 1302–1312 (2021).
- Braun, P. R. *et al.* Genome-wide DNA methylation comparison between live human brain and
  peripheral tissues within individuals. *Transl. Psychiatry 2019 91* 9, 1–10 (2019).
- 756 67. Smith, B. H. et al. Cohort profile: Generation scotland: Scottish family health study (GS:
- 757 SFHS). The study, its participants and their potential for genetic research on health and illness.
- 758 Int. J. Epidemiol. 42, 689–700 (2013).

759	68.	Habota, T. et al. Cohort profile for the STratifying Resilience and Depression Longitudinally
760		(STRADL) study: A depression-focused investigation of Generation Scotland, using detailed
761		clinical, cognitive, and neuroimaging assessments. Wellcome Open Res. 4, 185 (2019).
762	69.	Gold, L. et al. Aptamer-based multiplexed proteomic technology for biomarker discovery.
763		<i>PLoS One</i> <b>5</b> , e15004 (2010).
764	70.	Seeboth, A. et al. DNA methylation outlier burden, health, and ageing in Generation Scotland
765		and the Lothian Birth Cohorts of 1921 and 1936. Clin. Epigenetics 12, 49 (2020).
766	71.	McCartney, D. L. et al. Investigating the relationship between DNA methylation age
767		acceleration and risk factors for Alzheimer's disease. Alzheimer's Dement. Diagnosis, Assess.
768		Dis. Monit. 10, 429–437 (2018).
769	72.	Amador, C. et al. Recent genomic heritage in Scotland. BMC Genomics 16, 437 (2015).
770	73.	Bollepalli, S., Korhonen, T., Kaprio, J., Anders, S. & Ollikainen, M. EpiSmokEr: A robust
771		classifier to determine smoking status from DNA methylation data. Epigenomics 11, 1469-
772		1486 (2019).
773	74.	Min, J. L., Hemani, G., Davey Smith, G., Relton, C. & Suderman, M. Meffil: efficient
774		normalization and analysis of very large DNA methylation datasets. <i>Bioinformatics</i> 34, 3983–
775		3989 (2018).
776	75.	Reinius, L. E. et al. Differential DNA Methylation in Purified Human Blood Cells:
777		Implications for Cell Lineage and Studies on Disease Susceptibility. PLoS One 7, e41361
778		(2012).
779	76.	A, S. et al. Automated classification of depression from structural brain measures across two
780		independent community-based cohorts. Hum. Brain Mapp. 41, 3922-3937 (2020).

- 781 77. Therneau, T. M. coxme: Mixed Effects Cox Models. R package version 2.2-16.
- 782 https://CRAN.R-project.org/package=coxme. Accessed April 2021. (2020).
- 783 78. prcomp function RDocumentation.
- 784 https://www.rdocumentation.org/packages/stats/versions/3.6.2/topics/prcomp.
- 785 79. Zhang, F. *et al.* OSCA: A tool for omic-data-based complex trait analysis. *Genome Biol.* 20,
  786 (2019).
- 80. Gu, Z., Gu, L., Eils, R., Schlesner, M. & Brors, B. circlize implements and enhances circular
  visualization in R. *Bioinformatics* 30, 2811–2812 (2014).
- 81. (2017), R. C. T. R: A language and environment for statistical computing. R Foundation for
  Statistical Computing, Vienna, Austria.
- Watanabe, K., Taskesen, E., Van Bochoven, A. & Posthuma, D. Functional mapping and
  annotation of genetic associations with FUMA. *Nat. Commun. 2017 81* 8, 1–11 (2017).
- 83. Szklarczyk, D. et al. The STRING database in 2021: customizable protein–protein networks,
- and functional characterization of user-uploaded gene/measurement sets. *Nucleic Acids Res.*49, D605–D612 (2021).
- Võsa, U. *et al.* Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and
  polygenic scores that regulate blood gene expression. *Nat. Genet.* 2021 539 53, 1300–1310
  (2021).
- Kent, W. *et al.* UCSC Genome Browser: The human genome browser at UCSC. *Genome Res.*12, 996–1006 (2002).

801 86. Sloan, C. A. et al. ENCODE data at the ENCODE portal. Nucleic Acids Res. 44, D726–D732

- 802 (2016).
- 803 87. Li, D., Hsu, S., Purushotham, D., Sears, R. L. & Wang, T. WashU Epigenome Browser update
- 804 2019. Nucleic Acids Res. 47, W158–W165 (2019).

805

## 807 Figure legends

808 Figure 1. Integrated methylome and phenome study of the plasma proteome in relation to 809 brain health. Study design and key results are presented in this flow diagram. 1,065 individuals 810 from Generation Scotland had the levels of 4,058 plasma proteins (corresponding to 4,235 811 SOMAmers) measured. A methylome-wide association study (MWAS) of the 4,058 plasma protein 812 levels was conducted in 774 individuals that represented a nested subset of the full sample with 813 DNAm measurements available. This identified 2,928 CpG-protein (pQTM) associations. A 814 phenome-wide protein association study (Protein PheWAS) identified 191 protein levels that were 815 associated with a minimum of one brain health trait (N>=909). Integration of the protein MWAS and 816 PheWAS results identified 35 pQTMs that involved the levels of 17 protein markers of brain health 817 and 31 unique CpGs located in 20 genes.

818 Figure 2. Methylome-wide studies of 4,058 plasma proteins. a Summary of MWAS results for 4,058 protein levels in Generation Scotland (N=774). MWAS pQTMs that had  $P < 4.5 \times 10^{-10}$  in the 819 820 basic, white blood cell proportion (WBC)-adjusted and fully-adjusted models. Cis associations 821 (purple) and *trans* associations (green) are summarised for each model. Covariates used to adjust 822 DNAm are described for each model. Protein levels were adjusted for age, sex, 20 genetic principal 823 components (PCs) and technical variables and normalised prior to running MWAS. b Flow diagram 824 showing the distinction between the highly pleiotropic PAPPA and PRG3 protein pQTMs and the 825 pQTMs that involved the levels of a further 189 proteins. c Genomic locations for 825 of the 825 826 2,928 fully-adjusted pQTMs, excluding highly pleotropic associations for PAPPA and PRG3 protein 827 levels. Chromosomal location of CpG sites (x-axis) and protein genes (y-axis) are presented. The 434 828 *cis* pQTMs (purple) lay on the same chromosome and  $\leq 10$ Mb from the transcriptional start site 829 (TSS) of the protein gene, whereas the 391 *trans* pQTMs (green) lay > 10Mb from the TSS of the

protein gene or on a different chromosome. A list of the full association counts for each protein andCpG site can be found in Supplementary Tables 8-9.

Figure 3. Pleiotropic associations in the fully-adjusted MWAS. a pQTMs that had  $P < 4.5 \times 10^{-10}$ 832 833 in the fully-adjusted MWAS are plotted as individual points with chromosomal locations of the 191 834 protein genes (upper) and the 1,837 CpGs (lower) on the x-axis. 19 proteins with  $\geq$  10 associations 835 with CpGs are highlighted in turquoise and labelled on the upper plot. Nine CpGs with  $\geq 6$ 836 associations with protein levels are highlighted in turquoise on the lower plot. **b** Summary of genes 837 with highly pleiotropic CpG signals in the fully-adjusted MWAS. The fully-adjusted MWAS pQTMs 838 can be accessed in Supplementary Table 6. A list of the full association counts for each protein and CpG site can be found in Supplementary Tables 8-9. 839 840 Figure 4. PheWAS of 4.058 plasma proteins and brain health. a Number of protein marker associations with  $P < 3.5 \times 10^{-4}$  for each of the 15 traits related to brain health in the phenome-wide 841 842 protein association studies (protein PheWAS). These studies included a maximum sample of 1,065 843 individuals with protein measurements from Generation Scotland and tested for associations between 844 15 phenotypes and the levels of 4,058 plasma proteins. Cognitive score (turquoise), brain imaging 845 (light blue) and APOE e4 status (dark blue) associations are summarised. b Heatmap of standardised beta coefficients for 77 of the 405 protein PheWAS associations ( $P < 3.5 \times 10^{-4}$ ) indicated by an 846 847 asterisk. They include three proteins that had associations with both APOE e4 status and one or more 848 cognitive scores, in addition to 22 proteins that had associations with both a brain imaging measure 849 and a cognitive score. Negative and positive beta coefficients are shown in blue and red, 850 respectively. A heatmap describing the full 405 associations for APOE e4 status, cognitive scores 851 and brain imaging measures is available in Supplementary Fig. 6. Full summary statistics for the 405 852 associations are presented in Supplementary Table 17 and the subset of 77 associations shown in part 853 b can be accessed in Supplementary Table 18.

Figure 5. pQTMs involving protein markers of brain health. Circular plot showing 15 *trans* pQTM associations between DNAm at 11 CpG sites and the levels of nine proteins that were associated with one of more of the neurological phenotypes ( $P < 3.5 \times 10^{-4}$ ). Chromosomal positions are given on the outermost circle. Full details of the 35 pQTMs, including 20 *cis* associations are reported in Supplementary Table 20.

859 Figure 6. Integration of candidate marker associations. a Three trans associations with the CpG 860 site cg06690548 in the SLC7A11 gene, which encodes a synaptic protein that is linked to 861 environmental mediation in Parkinson's disease and is involved in glutamate transmission and 862 oxidative stress. b Five trans associations between CpGs in the ITIH3/ITIH1/NEK4 region on chromosome 3 and the levels of RBL2, which was associated with reductions in Global Grey Matter 863 864 Volume. c Two trans associations between DNAm at cg11294350 in the CHPT1 gene and two 865 proteins with lysosomal-associated function (SMPD1 and HEXB) that were associated with higher 866 Relative Brain Age and lower General Fractional Anisotropy. Associations with a positive beta 867 coefficient are denoted as red connecting lines, whereas associations with a negative beta coefficient 868 are denoted as blue connecting lines. The full 15 trans associations and 20 cis associations can be 869 found in Supplementary Table 20.





**Protein levels adjusted for:** Age, Sex, pQTLs, technical covariates, 20 genetic PCs **Association threshold:** P < 4.5x10<sup>-10</sup>

N=774 individuals, N=4,058 protein levels (4,235 SOMAmer measurements)







Number of associations with protein levels



b



